Table 1. OR of outcome measures from the RCT’s.
| Trial | OS | DFS | RFS | CBC |
|---|---|---|---|---|
| MA 17 | 1.03 (0.77–1.37) | 1.07 (0.79–1.44) | 1.02 (0.76–1.36) | 1.02 (0.76–1.36) |
| ABCSG 6a | 1.3 (0.93–1.81) | – | 1.29 (0.93–1.78) | 1.27 (0.92–1.74) |
| NSABP-33 | 0.979 (0.72–1.31) | 1.01 (0.74–1.38) | 1.01 (0.74–1.37) | – |
| NSABP-42 | 0.99 (0.74–1.34) | 1.05 (0.77–1.38) | 1.04 (0.77–1.4) | 1.03 (0.76–1.38) |
| DATA | 1.01 (0.74–1.37) | 1.06 (0.76–1.46) | 1.07 (0.78–1.47) | – |
| LATER | 1.02 (0.67–1.55) | 1.11 (0.73–1.67) | 1.17 (0.77–1.78) | – |
| IDEAL | 1.005 (0.74–1.36) | 1.01 (0.73–1.39) | 0.98 (0.73–1.32) | – |
| MA 17R | 0.98 (0.73–1.33) | 1.04 (0.77–1.41) | 1.01 (0.75–1.37) | – |
Data are presented as OR (95% CI). OS, overall survival; DFS, disease-free survival; RFS, recurrence-free survival; CBC, contralateral breast cancer; OR, odds ratio; RCT, randomized controlled trial.